Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2600133441Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai East Hospital. Primary endpoint: Pathological complete response. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
serplulimabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600133441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133441.